Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
465.31M | 399.25M | 330.38M | 274.33M | 206.53M | Gross Profit |
347.52M | 300.37M | 245.94M | 205.86M | 149.31M | EBIT |
-40.01M | -26.68M | -42.67M | -47.30M | -44.23M | EBITDA |
-18.53M | -8.11M | -29.50M | -36.85M | -33.61M | Net Income Common Stockholders |
-44.70M | -30.44M | -46.47M | 50.20M | -48.16M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
122.72M | 137.28M | 121.11M | 119.09M | 244.22M | Total Assets |
609.33M | 613.93M | 585.45M | 615.31M | 714.54M | Total Debt |
76.53M | 74.49M | 69.08M | 75.65M | 74.00M | Net Debt |
-46.19M | -9.82M | 10.98M | 31.99M | 32.06M | Total Liabilities |
148.36M | 147.76M | 128.69M | 131.56M | 302.14M | Stockholders Equity |
460.97M | 466.17M | 456.75M | 483.76M | 412.39M |
Cash Flow | Free Cash Flow | |||
12.20M | -37.51M | -39.02M | -23.53M | -25.13M | Operating Cash Flow |
12.20M | 4.48M | -22.14M | -13.78M | -19.87M | Investing Cash Flow |
30.23M | 21.82M | 44.01M | 23.50M | -156.20M | Financing Cash Flow |
-3.60M | -32.00K | -7.06M | -7.64M | 189.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $112.39B | 26.63 | 8.42% | 3.18% | 2.72% | 4.48% | |
74 Outperform | $10.31B | 777.79 | 1.20% | ― | 12.86% | -84.18% | |
62 Neutral | $1.56B | ― | -9.64% | ― | 16.55% | -44.89% | |
59 Neutral | $154.76M | ― | -144.19% | ― | 0.55% | -8.47% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% |
On March 26, 2025, AtriCure, Inc. held its 2025 Investor Day at its headquarters in Mason, Ohio, which was also webcasted. The event highlighted the company’s strong market position and its commitment to innovation in treating Afib and post-surgical pain. AtriCure emphasized its significant market opportunity, with a focus on expanding its product portfolio and improving clinical guidelines and reimbursement access. The company has experienced consistent growth, serving over 500,000 patients, and continues to invest in research and development to drive future advancements.
AtriCure reported preliminary financial results for the fourth quarter and full year 2024, with anticipated revenue growth of approximately 17% compared to the previous year. The company expects continued momentum into 2025, with projected revenues of $517 million to $527 million and positive adjusted EBITDA of $40 million to $44 million, driven by strong performance in key product lines and market expansion efforts.